Differences in Stem Cell Marker and Osteopontin Expression in Primary and Recurrent Glioblastoma
Bülent Polat(University of Würzburg), Camelia‐Maria Monoranu(University of Würzburg)
Cited by 0
Related Papers
Randomized Phase II Trial of Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: CAO/ARO/AIO-12
|Journal of Clinical Oncology|2019|536
Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer
|JAMA Oncology|2021|349
α-Synuclein in Parkinson’s disease: causal or bystander?
|Journal of Neural Transmission|2019|114
Differences in stem cell marker and osteopontin expression in primary and recurrent glioblastoma
|Cancer Cell International|2022|23